Evidence map›Paper›PMID 28039018›Full record

ArticleClinical immunology (Orlando, Fla.)2017

Estrogen-regulated STAT1 activation promotes TLR8 expression to facilitate signaling via microRNA-21 in systemic lupus erythematosus.

Nicholas A Young, Giancarlo R Valiente, Jeffrey M Hampton, Lai-Chu Wu, Craig J Burd, William L Willis, Michael Bruss, Holly Steigelman, Maya Gotsatsenko, Stephanie A Amici and 6 more

Open access · hybridAbstract read
In one paragraph

Article in Clinical immunology (Orlando, Fla.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. miR-574-5p in epigenetic regulation and Toll-like receptor signaling.Cell communication and signaling : CCS · 2024
    Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 2 countries.

Nicholas A YoungDivision of Rheumatology and Immunology, Wexner Medical Center at The Ohio State University, Columbus, OH 43210, USA; Department of Internal Medicine, Wexner Medical Center at The Ohio State University, Columbus, OH 43210, USA.
Giancarlo R ValienteDivision of Rheumatology and Immunology, Wexner Medical Center at The Ohio State University, Columbus, OH 43210, USA; Department of Internal Medicine, Wexner Medical Center at The Ohio State University, Columbus, OH 43210, USA.
Jeffrey M HamptonDivision of Rheumatology and Immunology, Wexner Medical Center at The Ohio State University, Columbus, OH 43210, USA; Department of Internal Medicine, Wexner Medical Center at The Ohio State University, Columbus, OH 43210, USA.
Lai-Chu WuDivision of Rheumatology and Immunology, Wexner Medical Center at The Ohio State University, Columbus, OH 43210, USA; Department of Internal Medicine, Wexner Medical Center at The Ohio State University, Columbus, OH 43210, USA.
Craig J BurdDepartment of Molecular Genetics, Wexner Medical Center at The Ohio State University, Columbus, OH 43210, USA.
William L WillisDivision of Rheumatology and Immunology, Wexner Medical Center at The Ohio State University, Columbus, OH 43210, USA; Department of Internal Medicine, Wexner Medical Center at The Ohio State University, Columbus, OH 43210, USA.
Michael BrussDivision of Rheumatology and Immunology, Wexner Medical Center at The Ohio State University, Columbus, OH 43210, USA; Department of Internal Medicine, Wexner Medical Center at The Ohio State University, Columbus, OH 43210, USA.
Holly SteigelmanDivision of Rheumatology and Immunology, Wexner Medical Center at The Ohio State University, Columbus, OH 43210, USA; Department of Internal Medicine, Wexner Medical Center at The Ohio State University, Columbus, OH 43210, USA.
Maya GotsatsenkoDivision of Rheumatology and Immunology, Wexner Medical Center at The Ohio State University, Columbus, OH 43210, USA; Department of Internal Medicine, Wexner Medical Center at The Ohio State University, Columbus, OH 43210, USA.
Stephanie A AmiciSchool of Health and Rehabilitation Sciences, Division of Medical Laboratory Science, and Department of Neuroscience, Wexner Medical Center at The Ohio State University, Columbus, OH 43210, USA.
Mary SeverinDepartment of Microbial Infection and Immunity, Wexner Medical Center at The Ohio State University, Columbus, OH 43210, USA.
Lucila Marino ClaverieDepartment of Rheumatology, Hospital Bernardino Rivadavia, Buenos Aires, Argentina.
Mireia Guerau-de-ArellanoSchool of Health and Rehabilitation Sciences, Division of Medical Laboratory Science, and Department of Neuroscience, Wexner Medical Center at The Ohio State University, Columbus, OH 43210, USA.
Amy Lovett-RackeDepartment of Microbial Infection and Immunity, Wexner Medical Center at The Ohio State University, Columbus, OH 43210, USA.
Stacy ArdoinDivision of Rheumatology and Immunology, Wexner Medical Center at The Ohio State University, Columbus, OH 43210, USA; Department of Internal Medicine, Wexner Medical Center at The Ohio State University, Columbus, OH 43210, USA.
Wael N JarjourDivision of Rheumatology and Immunology, Wexner Medical Center at The Ohio State University, Columbus, OH 43210, USA; Department of Internal Medicine, Wexner Medical Center at The Ohio State University, Columbus, OH 43210, USA. Electronic address: Wael.Jarjour@osumc.edu.
The Ohio State University Wexner Medical Center · USBernardino Rivadavia Natural Sciences Museum · AR

Funding

The Ohio State University Center for clinical and Translational ScienceUL1TR001070 · NCATS · OHIO STATE UNIVERSITY · PI JACKSON, REBECCA D · 2013 to 2017
$22.6M
Epigenetic modulation of T cell tolerance in Multiple Sclerosis autoimmunityR01AI121405 · NIAID · OHIO STATE UNIVERSITY · PI GUERAU-DE-ARELLANO, MIREIA · 2016 to 2020
$2.2M
Chromatin Dynamics of Endocrine Disruptor Compounds on Estrogen Receptor FunctionR00ES019918 · NIEHS · OHIO STATE UNIVERSITY · PI BURD, CRAIG J · 2013 to 2015
$729k
Novel Epigenetic Modifier Inhibitor Drugs for T cell Modulation in Multiple SclerosisR21AI127354 · NIAID · OHIO STATE UNIVERSITY · PI GUERAU-DE-ARELLANO, MIREIA · 2017 to 2018
$404k
NCATS NIH HHS UL1 TR001070NIAID NIH HHS R01 AI121405NIAID NIH HHS R21 AI127354NIEHS NIH HHS R00 ES019918
6 · The paper itself

Abstract

Recent studies implicate innate immunity to systemic lupus erythematosus (SLE) pathogenesis. Toll-like receptor (TLR)8 is estrogen-regulated and binds viral ssRNA to stimulate innate immune responses, but recent work indicates that microRNA (miR)-21 within extracellular vesicles (EVs) can also trigger this receptor. Our objective was to examine TLR8 expression/activation to better understand sex-biased responses involving TLR8 in SLE. Our data identify an estrogen response element that promotes STAT1 expression and demonstrate STAT1-dependent transcriptional activation of TLR8 with estrogen stimulation. In lieu of viral ssRNA activation, we explored EV-encapsulated miR-21 as an endogenous ligand and observed induction of both TLR8 and cytokine expression in vitro. Moreover, extracellular miR detection was found predominantly within EVs. Thus, just as a cytokine or chemokine, EV-encapsulated miR-21 can act as an inflammatory signaling molecule, or miRokine, by virtue of being an endogenous ligand of TLR8. Collectively, our data elucidates a novel innate inflammatory pathway in SLE.

Indexed as

Cell Line, TumorChemokinesEstrogensHumansImmunity, InnateInflammationLigandsLupus Erythematosus, SystemicMCF-7 CellsMicroRNAsSignal TransductionSTAT1 Transcription FactorToll-Like Receptor 8ChemokinesEstrogensLigandsMicroRNAsMIRN21 microRNA, humanSTAT1 protein, humanSTAT1 Transcription FactorTLR8 protein, humanToll-Like Receptor 8EstrogenExtracellular vesiclesInnate immunitymicroRNA (miR)Systemic lupus erythematosusToll-like receptor (TLR)8

Identifiers

PMID28039018
PMCPMC5815376
OpenAlexW2561975906

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.